NASDAQ:AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc.'s revenue fell 1.7% in fiscal 2025 to $719.9M while operating margin fell to 19.5%. Free cash flow was $121.2M, 16.8% of revenue, and the diluted share count fell 7.4%.Summary generated from Amphastar Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$719.9M
Revenue growth−1.7%
Revenue, 5-yr CAGR+15.5%
Gross margin49.5%
Operating margin19.5%
Net margin13.6%
ROIC9.2%
Return on equity12.9%
Debt / equity0.79
Free cash flow$121.2M
FCF margin16.8%
Share count change−7.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 438 | 499 | 644 | 732 | 720 |
| Operating income | 70 | 107 | 197 | 205 | 140 |
| Net income | 62 | 91 | 138 | 160 | 98 |
| Free cash flow | 71 | 65 | 145 | 172 | 121 |
Recent filings
- 4Insider transaction report
Sep 23, 2026 - 4Insider transaction report
Sep 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jul 13, 2026 - 8-KOther events
Jul 8, 2026 - 8-KResults of a shareholder vote
Jun 3, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026